The Cervical Dystonia market is experiencing intense competition and significant advancements, with leading companies like Ipsen, Merz, and AbbVie driving therapeutic innovations through strategic expansions. The global analysis from 2025-2035 forecasts a dynamic period of progress in treatment options. This competitive environment is highly beneficial for patients, promising better outcomes and more effective therapies. Pharmaceutical companies must continue their focus on research and development to meet the evolving needs of patients.